Septerna (NASDAQ:SEPN) Trading Up 2.4% - Time to Buy?

Key Points

• Septerna's stock rose by 2.4% to $13.88, with a trading volume decline of 33% from the average.
• Multiple analysts have raised their price targets for Septerna, with Cantor Fitzgerald setting a new target of $25.00 and Wells Fargo increasing it to $18.00.
• The company reported a loss of ($0.49) earnings per share, missing analysts' expectations by $0.11, and analysts project a consensus earnings outlook of -$7.11 for the fiscal year.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price traded up 2.4% during trading on Friday . The stock traded as high as $13.94 and last traded at $13.88. 202,547 shares traded hands during trading, a decline of 33% from the average session volume of 302,506 shares. The stock had previously closed at $13.56.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wells Fargo & Company upped their target price on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research note on Friday, May 16th. HC Wainwright assumed coverage on shares of Septerna in a research note on Monday, June 23rd. They set a "buy" rating and a $26.00 target price for the company. Finally, Cantor Fitzgerald upped their target price on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $26.75.

Septerna Stock Down 6.6%

The business's 50 day moving average price is $10.91 and its 200-day moving average price is $9.63.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. Sell-side analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Hedge Funds Weigh In On Septerna

A number of hedge funds have recently made changes to their positions in SEPN. RA Capital Management L.P. acquired a new position in shares of Septerna in the 4th quarter valued at $160,205,000. TRV GP V LLC acquired a new position in shares of Septerna in the 4th quarter valued at $142,337,000. TRV GP VI LLC acquired a new stake in shares of Septerna during the 4th quarter worth about $72,191,000. Samsara BioCapital LLC acquired a new stake in shares of Septerna during the 4th quarter worth about $63,399,000. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Septerna during the 4th quarter worth about $59,301,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.